Phase III Randomized, Intergroup Trial Assessing The Clinical Activity Of STI-571 [imatinib] At Two Dose Levels In Patients With Unresectable Or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing The KIT Receptor Tyrosine Kinase (CD117).
Latest Information Update: 10 Mar 2022
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 13 Feb 2009 New source identified and integrated (ClinicalTrials.gov).
- 04 Sep 2007 New trial record.